Preventive use of carvedilol for anthracycline-induced cardiotoxicity: a  systematic review and meta-analysis of randomized controlled trials.

CONCLUSION: Preventive use of carvedilol in patients undergoing anthracycline-based chemotherapy may be associated with a reduced incidence of LVSD, higher LVEF value, better diastolic function, and lower troponin I level. RCTs with larger sample size and longer follow-up are needed to verify these findings. PMID: 30656389 [PubMed - as supplied by publisher]
Source: Herz - Category: Cardiology Tags: Herz Source Type: research